Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 30

Sort by

Sort Order Select

Journal Articles

A Phase 2 Study of Daratumumab in Combination with Thalidomide and Dexamethasone in Relapsed and / or Refractory Myeloma: A Report from the Asian Myeloma Network

Wei-Ying Jen, Melissa Ooi, Sanjay De Mel, Cinnie Soekojo, Sung-Soo Yoon, Xinhua Li, Neha Awasthi, Sarah M Burkill, Brian GM Durie, Wee-Joo Chng

Blood (2023) 142 (Supplement 1): 2009.

https://doi.org/10.1182/blood-2023-180017

Published: 2023

Journal Articles

Monoclonal Gammopathy of Undetermined Significance and the Risk of Thrombotic Events: Results from Istopmm, a Population-Based Screening Study in Iceland

Blood (2023) 142 (Supplement 1): 216.

https://doi.org/10.1182/blood-2023-186098

Published: 2023

Journal Articles

Sars-Cov-2 Infection Does Not Lead to Progression of Monoclonal Gammopathy of Undetermined Significance: Results from the Population-Based Istopmm Screening Study

Blood (2023) 142 (Supplement 1): 4766.

https://doi.org/10.1182/blood-2023-173078

Published: 2023

Journal Articles

Predicting an Underlying Clonal Plasma Cell Population in Light-Chain Monoclonal Gammopathy of Undetermined Significance Using Free Light-Chain Ratio

Blood (2023) 142 (Supplement 1): 530.

https://doi.org/10.1182/blood-2023-182661

Published: 2023

Journal Articles

Randomized Phase 3 Study of Pomalidomide Cyclophosphamide Dexamethasone (PCD) Versus Pomalidomide Dexamethasone (PD) in Relapse or Refractory Myeloma: An Asian Myeloma Network (AMN) Study

Yang Song, Jin Seok Kim, CS Chim, Je-Jung Lee, Sung-Soo Yoon, Soo Chin Ng, Gin Gin Gan, Hiroshi Handa, Wei-Ying Jen, Xinhua Li, Yogesh Mahadev Pokharkar, Brian GM Durie, Wee-Joo Chng

Blood (2023) 142 (Supplement 1): 1009.

https://doi.org/10.1182/blood-2023-184723

Published: 2023

Journal Articles

Impact of Dexamethasone (Dex) Dose Strength on Outcomes in Newly Diagnosed Multiple Myeloma (NDMM): A Secondary Analysis of SWOG Studies S0777 and S1211

Rahul Banerjee, Rachael Sexton, Andrew J. Cowan, Sikander Ailawadhi, S. Vincent Rajkumar, Shaji Kunnathu Kumar, Sagar Lonial, Bart Barlogie, Brian GM Durie, Saad Z Usmani, Antje Hoering, Robert Z. Orlowski

Blood (2023) 142 (Supplement 1): 1066.

https://doi.org/10.1182/blood-2023-181744

Published: 2023

Journal Articles

Risk Factors of Smoldering Multiple Myeloma: Results from the Screened Istopmm Study

Blood (2023) 142 (Supplement 1): 3397.

https://doi.org/10.1182/blood-2023-188469

Published: 2023

Journal Articles

Daratumumab Bortezomib and Dexamethasone in Transplant Ineligible Newly Diagnosed Elderly Myeloma Patients - a Trial By Asian Myeloma Network

Chandramouli Nagarajan, Melinda Tan, Yunxin Chen, Melissa Ooi, Sanjay De Mel, Allison Tso, Lawrence Ng, Hein Than, Yeow Tee Goh, Brian GM Durie, Wee-Joo Chng

Blood (2023) 142 (Supplement 1): 6721.

https://doi.org/10.1182/blood-2023-173476

Published: 2023

Journal Articles

Real-World Evaluation of Teclistamab for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM)

Sireesha Asoori, Rakesh Popat, Joaquín Martínez-Lopez, Efstathios Kastritis, Larissa Brunaldi, Radhika Bansal, Andre De Menezes Silva Corraes, Kwee Yong, Catriona Mactier, Magdalena Corona, Adolfo Jesús Sáez Marín, Despina Fotiou, Meletios Athanasios Dimopoulos, Saurabh Chhabra, Sikander Ailawadhi, Ricardo Parrondo, Thomas Martin, Brian GM Durie, Yi Lin

Blood (2023) 142 (Supplement 1): 3347.

https://doi.org/10.1182/blood-2023-190793

Published: 2023

Journal Articles

Revised Definition of Free Light Chains in Serum and Light Chain Monoclonal Gammopathy of Undetermined Significance: Results of the Istopmm Study

Blood (2023) 142 (Supplement 1): 535.

https://doi.org/10.1182/blood-2023-188547

Published: 2023

Journal Articles

The Early Benefits and Psychological Effects of Screening for Monoclonal Gammopathy of Undetermined Significance: Results of the Istopmm Study

Blood (2023) 142 (Supplement 1): 214.

https://doi.org/10.1182/blood-2023-186397

Published: 2023

Journal Articles

Imaging Practices in Patients with Plasma Cell Dyscrasias across the Asian Myeloma Network - Survey Results and Recommendations

Natasha Fay Anthony, Wenming Chen, Chim James, Gin Gin Gan, Jeffrey Huang, Kihyun Kim, Teeraya Puavilai, Wee-Joo Chng, Kazuyuki Shimizu, Brian GM Durie, Chandramouli Nagarajan

Blood (2023) 142 (Supplement 1): 6666.

https://doi.org/10.1182/blood-2023-173228

Published: 2023

Journal Articles

Survival in Patients with Relapsed/Refractory Multiple Myeloma: Outcomes after 4 Years of the Ongoing Multinational Observational Preamble Study

Gordon Cook, David Cella, PhD, Clara Chen, PhD BS, MS, Catherine Davis, PharmD, Brian GM Durie, MD, Hartmut Goldschmidt, MD, David J. Kuter, MD, Philippe Moreau, Ravi Vij, MBBS

Blood (2018) 132 (Supplement 1): 3285.

https://doi.org/10.1182/blood-2018-99-112081

Published: 2018

Journal Articles

Indirect Comparison Using Individual Patient Level Data Comparing Efficacy and Safety of a Daratumumab Monotherapy Vs. EU Approved Comparator Therapies in Patients with Multiple Myeloma

Irina Demmer, Susanne Huschens, Dietrich Potthoff, Jörg Tomeczkowski, Christian Englisch, Pushpike Thilakarathne, Joris Diels, Shaji K. Kumar, MD, Brian GM Durie, MD, Lewin Eisele

Blood (2018) 132 (Supplement 1): 3541.

https://doi.org/10.1182/blood-2018-99-116884

Published: 2018

Journal Articles

Characterization of Patients with Multiple Myeloma in Long- Term Remission

Raphael K. Lutz, MD, Katharina Kriegsmann, MD MBA, Mohamed H.S. Awwad, Carsten Müller-Tidow, MD, Gerlinde Egerer, Nicola Lehners, Marc S Raab, MD PhD, Brian GM Durie, MD, Michael Hundemer, Hartmut Goldschmidt, MD

Blood (2018) 132 (Supplement 1): 4508.

https://doi.org/10.1182/blood-2018-99-116039

Published: 2018

Journal Articles

Longer Term Follow up of the Â Randomized Phase III Trial SWOG S0777: Bortezomib, Lenalidomide and Dexamethasone Vs. Lenalidomide and Dexamethasone in Patients (Pts) with Previously Untreated Multiple Myeloma without an Intent for Immediate Autologous Stem Cell Transplant (ASCT)

Brian GM Durie, MD, Antje Hoering, PhD, Rachael Sexton, PhD, Muneer H. Abidi, MD, Joshua Epstein, DSc, S. Vincent Rajkumar, MD, Angela Dispenzieri, MD, Stephen P. Kahanic, MD, Mohan C. Thakuri, MD, Frederic J. Reu, MD, Christopher M. Reynolds, MD, Robert Z. Orlowski, MD PhD, Bart Barlogie, MD PhD

Blood (2018) 132 (Supplement 1): 1992.

https://doi.org/10.1182/blood-2018-99-117003

Published: 2018

Journal Articles

Carfilzomib Thalidomide and Dexamethasone Is Safe and Effective in the Treatment of Relapsed/Refractory Multiple Myeloma: Preliminary Outcome from the Open Label Phase II ALLGMM018/AMN003 Study

Hang Quach, MDFRACP,FRCPA,MBBS, Simon J. Harrison, MBBS,MRCP,FRCPath,FRACP,PhD, Slavisa Ninkovic, MBBS FRACP FRCPA, Jane Estell, MBBS FRACP, Noemi Horvath, MBBS FRACP FRCPA, Nick Murphy, MBBS FRACP FRCPA, Richard Eek, MBCHB, Bradley Augustson, MBBS FRACP FRCPA, Philip Campbell, MBBS, FRACP, FRCPA, Rajeev Rajagopal, Akash Kalro, MD, Robyn Hemme, Belinda Butcher, BSc(Hons) MBiostat PhDCMPP AStat, Tracey Gerber, Peter Mollee, FRACP, FRCPA, MBBS, MMSc, Brian GM Durie, MD, Wee-Joo Chng, MBBS, PhD FRCPath, FRCP

Blood (2018) 132 (Supplement 1): 1955.

https://doi.org/10.1182/blood-2018-99-111434

Published: 2018

Journal Articles

Treatment Choices and Outcomes for Patients with Multiple Myeloma after Relapse on Lenalidomide Maintenance Therapy: Results from the Connect ® MM Registry

Sundar Jagannath, MD, Mohit Narang, MD, Sikander Ailawadhi, Robert M Rifkin, MD, Howard R Terebelo, DO, Kathleen Toomey, MD, Brian GM Durie, MD, James W Hardin, PhD, Cristina J Gasparetto, MD, Lynne Wagner, PhD, James Omel, MD, Shankar Srinivasan, PhD MBA, Amani Kitali, MPH, MBA, Amit Agarwal, MD PhD, Rafat Abonour, MD

Blood (2018) 132 (Supplement 1): 3232.

https://doi.org/10.1182/blood-2018-99-110877

Published: 2018

Journal Articles

Phase I/II Dose Expansion Of a Multi-Center Trial Of Carfilzomib and Pomalidomide With Dexamethasone (Car-Pom-d) In Patients With Relapsed/Refractory Multiple Myeloma

Jatin J. Shah, M.D., Edward A. Stadtmauer, MD, Rafat Abonour, MD, Adam D. Cohen, MD, William Bensinger, MD, Cristina Gasparetto, MD, Jonathan L. Kaufman, MD, Suzanne Lentzsch, MD, PhD, Dan T. Vogl, MD, MSCE, Robert Z. Orlowski, M.D., Ph.D., Erica L. Kim, MPH, Natalia Bialas, David D. Smith, PhD, Brian GM Durie, MD

Blood (2013) 122 (21): 690.

https://doi.org/10.1182/blood.V122.21.690.690

Published: 2013

Journal Articles

Clinical Profile of Multiple Myeloma in Asia - an Asian Myeloma Network (AMN) Study

Blood (2012) 120 (21): 5035.

https://doi.org/10.1182/blood.V120.21.5035.5035

Published: 2012

NARROW

A Phase 2 Study of Daratumumab in Combination with Thalidomide and Dexamethasone in Relapsed and / or Refractory Myeloma: A Report from the Asian Myeloma Network

Monoclonal Gammopathy of Undetermined Significance and the Risk of Thrombotic Events: Results from Istopmm, a Population-Based Screening Study in Iceland

Sars-Cov-2 Infection Does Not Lead to Progression of Monoclonal Gammopathy of Undetermined Significance: Results from the Population-Based Istopmm Screening Study

Predicting an Underlying Clonal Plasma Cell Population in Light-Chain Monoclonal Gammopathy of Undetermined Significance Using Free Light-Chain Ratio

Randomized Phase 3 Study of Pomalidomide Cyclophosphamide Dexamethasone (PCD) Versus Pomalidomide Dexamethasone (PD) in Relapse or Refractory Myeloma: An Asian Myeloma Network (AMN) Study

Impact of Dexamethasone (Dex) Dose Strength on Outcomes in Newly Diagnosed Multiple Myeloma (NDMM): A Secondary Analysis of SWOG Studies S0777 and S1211

Risk Factors of Smoldering Multiple Myeloma: Results from the Screened Istopmm Study

Daratumumab Bortezomib and Dexamethasone in Transplant Ineligible Newly Diagnosed Elderly Myeloma Patients - a Trial By Asian Myeloma Network

Real-World Evaluation of Teclistamab for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM)

Revised Definition of Free Light Chains in Serum and Light Chain Monoclonal Gammopathy of Undetermined Significance: Results of the Istopmm Study

The Early Benefits and Psychological Effects of Screening for Monoclonal Gammopathy of Undetermined Significance: Results of the Istopmm Study

Imaging Practices in Patients with Plasma Cell Dyscrasias across the Asian Myeloma Network - Survey Results and Recommendations

Survival in Patients with Relapsed/Refractory Multiple Myeloma: Outcomes after 4 Years of the Ongoing Multinational Observational Preamble Study

Indirect Comparison Using Individual Patient Level Data Comparing Efficacy and Safety of a Daratumumab Monotherapy Vs. EU Approved Comparator Therapies in Patients with Multiple Myeloma

Characterization of Patients with Multiple Myeloma in Long- Term Remission

Longer Term Follow up of the Â Randomized Phase III Trial SWOG S0777: Bortezomib, Lenalidomide and Dexamethasone Vs. Lenalidomide and Dexamethasone in Patients (Pts) with Previously Untreated Multiple Myeloma without an Intent for Immediate Autologous Stem Cell Transplant (ASCT)

Carfilzomib Thalidomide and Dexamethasone Is Safe and Effective in the Treatment of Relapsed/Refractory Multiple Myeloma: Preliminary Outcome from the Open Label Phase II ALLGMM018/AMN003 Study

Treatment Choices and Outcomes for Patients with Multiple Myeloma after Relapse on Lenalidomide Maintenance Therapy: Results from the Connect ® MM Registry

Phase I/II Dose Expansion Of a Multi-Center Trial Of Carfilzomib and Pomalidomide With Dexamethasone (Car-Pom-d) In Patients With Relapsed/Refractory Multiple Myeloma

Clinical Profile of Multiple Myeloma in Asia - an Asian Myeloma Network (AMN) Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only